An open-label, two-period, fixed sequence, crossover study with single oral dose of 20 mg lirafugratinib with and with-out itraconazole (strong CYP3A4 inhibitor) in healthy adult participants.
Latest Information Update: 21 Jan 2025
Price :
$35 *
At a glance
- Drugs Lirafugratinib (Primary) ; Itraconazole
- Indications Solid tumours
- Focus Pharmacokinetics
- 21 Jan 2025 New trial record